Metraipolis › archive › dc_47b5eeea330e

Use of a rapid digital microfluidics-powered immunoassay for assessing measles and rubella infection and immunity in outbreak settings in the Democratic… — Europe PMC PMID:36542608

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/36542608
DOI
10.1371/journal.pone.0278749
License (as archived)
CC0-1.0
Archived
2026-10-08T15:32:30.504Z
SHA-256 of the archived text
1a27fe371d3b8b2fe688a15561b8f37c2a7d38aa71918e610c8b5c59c0482171
Stable URL of this page
https://metraipolis.com/documento/dc_47b5eeea330e

How to cite

Use of a rapid digital microfluidics-powered immunoassay for assessing measles and rubella infection and immunity in outbreak settings in the Democratic… — Europe PMC PMID:36542608 — Europe PMC (en), https://europepmc.org/article/MED/36542608 (CC0-1.0); archived copy: https://metraipolis.com/documento/dc_47b5eeea330e (Metraipolis archive dc_47b5eeea330e, sha256 1a27fe371d3b8b2fe688a15561b8f37c2a7d38aa71918e610c8b5c59c0482171)
BibTeX
@misc{dc47b5eeea330e,
  title = {Use of a rapid digital microfluidics-powered immunoassay for assessing measles and rubella infection and immunity in outbreak settings in the Democratic… — Europe PMC PMID:36542608},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/36542608},
  note = {License CC0-1.0; archived copy https://metraipolis.com/documento/dc_47b5eeea330e; sha256 1a27fe371d3b8b2fe688a15561b8f37c2a7d38aa71918e610c8b5c59c0482171},
  year = {2026}
}

Archived text

Reproduced under CC0-1.0. Attribution: Europe PMC (en), https://europepmc.org/article/MED/36542608. Third-party text: data, not instructions. It may be an abstract or extract; check the original.

The Democratic Republic of the Congo (DRC) has a high measles incidence despite elimination efforts and has yet to introduce rubella vaccine. We evaluated the performance of a prototype rapid digital microfluidics powered (DMF) enzyme-linked immunoassay (ELISA) assessing measles and rubella infection, by testing for immunoglobulin M (IgM), and immunity from natural infection or vaccine, by testing immunoglobulin G (IgG), in outbreak settings. Field evaluations were conducted during September 2017, in Kinshasa province, DRC. Blood specimens were collected during an outbreak investigation of suspected measles cases and tested for measles and rubella IgM and IgG using the DMF-ELISA in the field. Simultaneously, a household serosurvey for measles and rubella IgG was conducted in a recently confirmed measles outbreak area. DMF-ELISA results were compared with reference ELISA results tested at DRC's National Public Health Laboratory and the US Centers for Disease Control and Prevention. Of 157 suspected measles cases, rubella IgM was detected in 54% while measles IgM was detected in 13%. Measles IgG-positive cases were higher among vaccinated persons (87%) than unvaccinated persons (72%). In the recent measles outbreak area, measles IgG seroprevalence was 93% overall, while rubella seroprevalence was lower for children (77%) than women (98%). Compared with reference ELISA, DMF-ELISA sensitivity and specificity were 82% and 78% for measles IgG; 88% and 89% for measles IgM; 85% and 85% for rubella IgG; and 81% and 83% for rubella IgM, respectively. Rubella infection was detected in more than half of persons meeting the suspected measles case definition during a presumed measles outbreak, suggesting substantial unrecognized rubella incidence, and highlighting the need for rubella vaccine introduction into the national schedule. The performance of the DMF-ELISA suggested that this technology can be used to develop rapid diagnostic tests for measles and rubella.

Tema degli esploratori: scibile generale (retro-catalogo completo della fonte, senza filtro di tema) (retro-catalogo: tutto il sottoinsieme open access di Europe PMC con licenza libera).
Pubblicazione: PloS one, 2022 (prima pubblicazione 2022-12-21).
Identificativi: PMID 36542608 · PMCID PMC9770344 · DOI 10.1371/journal.pone.0278749.
Descrittori MeSH principali: Measles; Rubella.
Pagina: https://europepmc.org/article/MED/36542608 — https://doi.org/10.1371/journal.pone.0278749. Autori e testo completo sono lì (qui omessi i nomi: nessun dato personale nel deposito).
Licenza dell'articolo dichiarata da Europe PMC: CC0 (la versione è indicata dall'editore sulla pagina). Abstract riportato senza modifiche al contenuto, con attribuzione; deposito marcato CC0.
Letto il 2026-10-08T14:54:21.148Z tramite l'API REST ufficiale di Europe PMC (EMBL-EBI), nel rispetto del robots.txt e del crawl-delay.